Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

20.3K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computer-aided image analysis for PD-L1 assessment in canine urothelial carcinoma.

Veterinary journal (London, England : 1997)·2026
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

Evaluation of the anti-inflammatory properties of Ascophyllum nodosum-derived fucoidan in dogs with canine chronic inflammatory enteropathy - results from an ex vivo study.

Polish journal of veterinary sciences·2025
Same author

Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma.

BMC veterinary research·2025
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Multimodal imaging of migrating gallbladder mucocele in a Chihuahua.

The Journal of small animal practice·2025

Related Experiment Video

Updated: Mar 14, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Tyrosine Kinase Receptor Expression in Canine Liposarcoma.

G Avallone1, V Pellegrino1, P Roccabianca2

  • 11 Department of Veterinary Medical Sciences (DIMEVET), University di Bologna, Ozzano dell'Emilia, Italy.

Veterinary Pathology
|October 5, 2016
PubMed
Summary

Tyrosine kinase receptor expression in canine liposarcoma was studied. High expression of FGF2, FGFR1, PDGFB, and PDGFRβ suggests PDGFRβ may be a target for canine cancer therapies.

Keywords:
FGF2PDGFRβcanineliposarcomasoft tissue sarcomatyrosine kinase receptor

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.5K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.5K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Area of Science:

  • Veterinary oncology
  • Molecular pathology
  • Cancer biology

Background:

  • Tyrosine kinase receptors (TKRs) are crucial in cancer, serving as therapeutic targets.
  • Limited data exists on TKR expression in canine liposarcoma (LP), a common soft tissue sarcoma.
  • Understanding these pathways is key for developing targeted adjuvant therapies in veterinary medicine.

Purpose of the Study:

  • To investigate the immunohistochemical expression of fibroblast growth factor receptor 1 (FGFR1), platelet-derived growth factor receptor-β (PDGFRβ), their ligands (FGF2, PDGFB), and c-kit in canine liposarcoma.
  • To correlate TKR expression with tumor grade and proliferation markers.
  • To identify potential therapeutic targets for canine LP.

Main Methods:

  • Fifty canine liposarcoma samples were analyzed using immunohistochemistry.
  • Expression levels of FGF2, FGFR1, PDGFB, PDGFRβ, and c-kit were categorized as high or low.
  • Correlations between receptor expression, mitotic count, and MIB-1 proliferation index were assessed.

Main Results:

  • High expression of FGF2 (62%), FGFR1 (68%), PDGFB (81.6%), and PDGFRβ (70.8%) was observed in canine LPs.
  • c-kit expression was found in 12.5% of cases.
  • Mitotic count negatively correlated with FGF2 and positively correlated with PDGFRβ expression.

Conclusions:

  • The PDGFRβ-mediated pathway appears to play a role in canine liposarcoma progression.
  • PDGFRβ represents a potential and promising target for novel adjuvant cancer therapies in dogs.
  • Further research into TKR signaling pathways could improve treatment strategies for canine soft tissue sarcomas.